Cyient Share Buyback: Last Chance to Buy Shares for Rs 720 Crore Offer

Engineering and technology services major Cyient is moving forward with its Rs 720 crore share buyback program, offering investors a significant premium over current market prices. For those looking to participate, understanding the critical deadlines and eligibility criteria is essential to ensuring your shares are credited in time.

Critical Deadlines and Eligibility Criteria

Investors must act quickly if they wish to benefit from this corporate action. Cyient has fixed June 17 (Wednesday) as the record date for the buyback. Under SEBI’s T+1 settlement norms, shares must be credited to an investor's demat account by the record date to establish ownership.

Consequently, June 16 (Tuesday) serves as the final deadline to purchase Cyient shares. Only shareholders who hold the company's stock in their demat accounts as of the record date on Wednesday will be eligible to tender their shares for the repurchase.

Key Details of the Rs 720 Crore Buyback

This marks Cyient’s first share buyback since 2019. The company has announced plans to repurchase up to 64 lakh shares at a fixed price of Rs 1,125 per share. This offer price represents a substantial premium of more than 25% over the stock's previous closing price.

While the shareholders have officially approved the buyback, the company is yet to announce the specific entitlement ratio and further operational details. Typically, companies initiate buybacks to utilize surplus cash, increase shareholder value, or bolster promoter holdings.

Stock Performance and Market Outlook

Despite the attractive buyback price, Cyient's stock has faced recent volatility. On Tuesday morning, shares traded at approximately Rs 886, reflecting a slight drop of over 1%. Looking at the broader timeframe, the stock has seen significant pressure, down over 20% in 2024 and falling 33% over the last year. However, the company maintains a robust market capitalization of more than Rs 9,853 crore.

市場アナリストは、同社の当面の軌道に対して慎重な姿勢を維持しています。EmkayはCyient株に対して「リデュース（売り推奨）」の判断を維持していますが、目標株価については従来の850ルピーから900ルピーへとわずかに引き上げました。同証券会社は、マクロ経済の逆風や、世界的なサプライチェーンの問題に起因するDLMの在庫回転日数の課題により、2026年度（FY26）の成長が鈍化すると指摘しています。それでもなお、経営陣は2027年度（FY27）に向けて、より強力で収益性の高い成長を実現することに楽観的な見方を示しています。

主なポイント